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ABSTRACT
DGCR8/Pasha is an essential cofactor for Drosha, a
nuclear RNase III that cleaves the local hairpin
structures embedded in long primary microRNA
transcripts (pri-miRNAs) in eukaryotes. Although
our knowledge of pri-miRNA processing has sig-
nificantly advanced in recent years, the precise role
of DGCR8 in this pathway remains unclear. In our
present study, we dissect the domains in DGCR8
that contribute to the processing of pri-miRNAs and
the subcellular localization of DGCR8. Drosha is
stabilized through an interaction between its middle
domain and the conserved C-terminal domain of
DGCR8. Furthermore, DGCR8, but not Drosha, can
directly and stably interact with pri-miRNAs, and
the tandem dsRNA-binding domains (dsRBDs) in
DGCR8 are responsible for this recognition.
Moreover, the DGCR8 N-terminal region upstream
of its dsRBDs is unnecessary for pri-miRNA proces-
sing but is critical for nuclear localization. Our study
thus provides further insights into the mechanism
of action of the Drosha–DGCR8 complex in
pri-miRNA processing.
INTRODUCTION
MicroRNAs (miRNAs) constitute an abundant class of key
regulatory molecules that control diverse cellular functions in
eukaryotes, such as differentiation, development and antiviral
defense (1,2). These molecules are single-stranded RNAs
(ssRNAs) of  22 nt, which anneal to their target mRNA
molecules and induce speciﬁc degradation and translational
repression. Both computational and biological studies indicate
that each miRNA can target a number of different mRNAs,
and that  20–30% of human genes may be regulated by
these factors (3,4). Interestingly, the expression proﬁles of
the miRNAs often show a strong correlation with the disease
status of a cell [reviewed by Croce and Calin, (5)]. Further-
more, at least some of these miRNAs are likely to be involved
in tumorigenesis, as indicated in a recent study showing that
the over-expression of the miR-17 cluster, when co-expressed
with c-Myc, induces B cell lymphoma in mice (6). The tight
control of both the temporal and spatial expression of
miRNAs thus seems to be crucial for the maintenance of
cellular integrity. MiRNA expression appears to be regulated
at multiple stages during the biogenesis of these molecules,
although, it remains to be determined how this control
is achieved. The characterization of biogenesis factors will
therefore be of critical importance towards our increased
understanding of the miRNA-guided gene regulatory
network.
MiRNA biogenesis is initiated by transcription with
RNA polymerase II (7–9) and their primary transcripts (pri-
miRNAs) harbor a local hairpin structure that is then cropped
by a nuclear RNase III, Drosha, into  70 nt precursor-miRNAs
(pre-miRNAs) (10,11). Drosha functions in a complex known
as Microprocessor that also contains a dsRNA-binding pro-
tein, DGCR8 (DiGeorge syndrome chromosomal region 8;
also known as Pasha in Caenorhabditis elegans and Droso-
phila) (12–15). Pre-miRNAs then exit the nucleus via the
action of exportin-5 (Exp5) (16–18). Dicer, a cytoplasmic
RNase III nuclease, then removes the terminal loop of the pre-
miRNAs to generate the  22 nt miRNA duplex (19–23). One
strand of the duplex is then loaded onto the RNA induced
silencing complex (RISC) (24,25).
DsRNA-binding proteins that contain dsRNA-binding
domains (dsRBDs) serve diverse roles during RNA metabo-
lism. A recently emerging theme in RNA silencing pathways
is that multidomain RNase III proteins, such as Drosha and
Dicer, necessitate dsRNA-binding proteins for miRNA
processing and/or RISC formation (26–31). For example,
Dcr-1 in Drosophila interacts with Loquacious/R3D1 that
contains three dsRBDs and is required for miRNA processing,
and possibly also for RISC assembly (28–30,32). Further-
more, TRBP and PACT, the human homologues of
Loquacious/R3D1, interact with human Dicer and thereby
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biochemical functions of these proteins remain largely
unknown.
DGCR8/Pasha has been identiﬁed as a Drosha-interacting
protein in Drosophila by both yeast two hybrid screening
(13,15,35) and immunopuriﬁcation from human cells
(12,14). The human DGCR8 gene is located on chromosome
22q11 and is expressed ubiquitously from fetus to adult (36).
Monoallelic deletion of this genomic region is associated
with several clinical defects, most notably including
DiGeorge syndrome/conotruncal anomaly face syndrome/
velocardiofacial syndrome (37). In experiments in which
DGCR8 was depleted by RNAi, pri-miRNAs were found to
accumulate whereas pre-miRNA and mature miRNA levels
decreased. In addition, neither recombinant DGCR8 nor
Drosha alone was observed to be active during pri-miRNA
cleavage, whereas a combination of these factors restores
activity, indicating that DGCR8 is an essential cofactor for
Drosha (12,14). The addition of recombinant DGCR8
also slightly reduced non-speciﬁc cleavage by Drosha (14).
Because DGCR8/Pasha contains two dsRBDs at the
C-terminus, it is thought that this cofactor facilitates the inter-
action of Drosha with its substrate RNA. DGCR8 also con-
tains a putative WW domain (also termed Rsp5/wwp) in its
middle region, which contains two highly conserved trypto-
phan residues separated by  20 amino acids (38). Because
the WW domain is known to interact with both proline-rich
motifs (39) and Drosha is proline-rich at its N-terminus, it
has been proposed that DGCR8 may interact with Drosha
through its WW domain.
In our current study, we examine how the various
DGCR8 domains contribute to Drosha interaction, and
to RNA recognition and subcellular localization. Our ﬁnd-
ings further our understanding of the mechanism of action
of the Drosha–DGCR8 complex during pri-miRNA
processing.
MATERIALS AND METHODS
Ultraviolet (UV)-crosslinking
A total of 20–50 ng of puriﬁed FLAG-DGCR8 and radiola-
beled RNAs of (1 · 10
6 c.p.m.; 50–100 fmol) were mixed
in 15 ml of binding buffer [10 mM Tris (pH 7.5), 50 mM
KCl, 0.5 mM DTT, 1 U of RNase inhibitor, TAKARA] in
96-well plates, and then incubated at 4 C for 30 min.
For competition assays, cold transcripts prepared by in vitro
transcription were added to the reaction mixtures. The
96-well plates containing the reaction mixture were then
placed in a UV-crosslinker (CL-1000 UV-crosslinker,
UVP) for 5 min. After treatment with an RNase A/T1
mixture, the reaction mixtures were loaded onto 7.5%
SDS–polyacrylamide gels.
In vitro protein binding assay
Immunopuriﬁed Drosha-FLAG proteins ( 2 mg) were immo-
bilized on 15 ml of anti-FLAG M2 agarose mouse afﬁnity gel
(Sigma) and incubated with 10
6 c.p.m. of in vitro translated
DGCR8 protein in 1 ml of buffer D-K0250 [20 mM Tris
(pH 8.0), 250 mM KCl, 0.2 mM EDTA, 0.2 mM phenylmeth-
lysulfonyl ﬂuoride (PMSF), 0.1% Triton X-100]. After incu-
bation for 90 min at 4 C, the resin was washed six times with
1 ml of buffer D-K0250 and the bound fraction was eluted by
boiling in 40 ml of SDS–PAGE sample buffer and resolved by
SDS–PAGE.
Purification of recombinant DGCR8 proteins
DGCR8 proteins fused to glutathione S-transferase (GST) at
the N-terminus were puriﬁed as described previously (12).
The GST tag was then removed from by incubation with
10 U/ml of thrombin at 16 C overnight. FLAG-DGCR8 pro-
teins were prepared as follows: four 10 cm dishes of
HEK293T cells were transfected with the FLAG-DGCR8
expression vector. Two days after transfection, the cells
were harvested and sonicated in 1.5 ml of ice-cold buffer
D-K0200 [20 mM Tris (pH 8.0), 200 mM KCl, 0.2 mM
EDTA and 0.2 mM PMSF]. After centrifugation at
13 200 r.p.m. at 4 C for 15 min, the supernatant was treated
with 50 mg/ml of RNase A at 4 C for 30 min. This extract
was then incubated with 30 ml of anti-FLAG antibody that
had been conjugated to agarose beads (anti-FLAG M2 agar-
ose mouse afﬁnity gel, Sigma) with constant rotation for
120 min at 4 C. The beads were then washed four times in
buffer D-Na02500 [20 mM Tris (pH 8.0), 2.5 M NaCl,
0.2 mM EDTA, 0.2 mM PMSF and 1% Triton X-100) to
remove DGCR8-interacting proteins from the FLAG-
DGCR8 protein. After three additional washings with
FLAG-elution buffer [50 mM Tris (pH 7.4) and 150 mM
NaCl], FLAG-DGCR8 proteins were eluted three times by
incubating the beads with FLAG-elution buffer containing
400 mg/ml of 3· FLAG peptide (Sigma) at 4 C for 60 min.
The eluant was then concentrated at 20 ng/ml using Centricon
YM-30 tubes (Millipore).
Preparation and labeling of substrate RNA
Pri-let-7a-1, pri-miR-16-1 and pri-miR-30a molecules were
prepared by in vitro transcription as described previously
(10,12). The labeling of pri-miR-16-1 at the 50 end was also
carried out as described previously (12).
In vitro processing of pri-miRNAs
In vitro processing of pri-miRNAs using either whole cell
extracts or FLAG-immunoprecipitates was carried out as
described previously (10,11). Brieﬂy, reactions were carried
out in 30 ml volumes containing either 15 ml of whole cell
extract or immunoprecipitation beads, and also comprising
6.4 mM MgCl2,1U / ml of Ribonuclease Inhibitor (TAKARA)
and labeled transcripts at 1 · 10
4–1 · 10
5 c.p.m.. The reaction
mixture was incubated at 37 C for 90 min, and RNA was
extracted by phenol and analyzed on a 12.5% denaturing
polyacrylamide gel.
Mutagenesis of DGCR8
PCR products of the DGCR8 deletion mutants were sub-
cloned into the EcoRI and NotI sites of the FLAG-pCK or
Nucleic Acids Research, 2006, Vol. 34, No. 16 4623V5-pcDNA3 vectors for expression in human cells. Point
mutagenesis of DGCR8 was carried out using a site-directed
mutagenesis kit (Stratagene) according to the manufacturer’s
instructions. The primer sequences used for mutagenesis are
shown in Supplementary Table.
Cell culture and transfection
HeLa cells and HEK293T cells were cultured in DMEM
(WelGENE) supplemented with 10% FBS (WelGENE).
Transfections were carried using the calcium-phosphate
method.
Gel retardation assay
A total of 50 ng of recombinant DGCR8 proteins puriﬁed
from Escherichia coli cells was mixed with radiolabeled
RNAs (5 · 10
5 c.p.m.) in 10 ml of reaction buffer [15 mM
HEPES (pH 7.4), 100 mM KOAc, 2 mM Mg(OAc)2,
5 mM DTT, 0.2 % BSA, 1 U of RNase Inhibitor, TAKARA]
and incubated at 4 C for 20 min. Samples were loaded
onto 4% non-denaturing polyacrylamide gel (acrylamide:
bis-acrylamide ¼ 39:1) and electrophoresed at 250 V
at 4 C.
Immunofluorescence
HeLa cells were grown on glass coverslips in DMEM, sup-
plemented with 10% FBS. Cell transfections were carried
out using the calcium-phosphate method. Two days after
transfection, the cells were ﬁxed using 2% formaldehyde
in phosphate-buffered saline (PBS) for 30 min, washed
with PBS and then permeabilized in PBS containing 0.1%
Triton X-100 for 15 min. After several washes, the cells
were saturated with 4% BSA in PBS for 30 min and immu-
nostained for 2 h at RT with rabbit anti-V5-tag serum
(Sigma) in PBS containing 4% BSA as the blocking
agent. Subsequently, the cells were washed with PBS and
incubated for 1 h at room temperature with Alexa Fluor
594 secondary antibody (Molecular Probes). The cells
were analyzed using an Axioplan2 (Carl Zeiss) ﬂuorescent
microscope.
RESULTS
DGCR8 interacts with Drosha through its conserved
C-terminal region
In order to determine the region required for the interac-
tion of DGCR8 with Drosha, ﬁve deletion mutants of
DGCR8 (DG276–773, DG484–773, DG1–483, DG1–614
and DG1–692) were tested (Figure 1). These truncation mut-
ants were prepared as
35S-methionine labeled proteins by TnT
(in vitro transcription and translation) reactions and incubated
with Drosha-FLAG proteins that had been immobilized on
anti-FLAG antibody-conjugated beads (Figure 2A, lanes
7–12). The expression plasmid encoding only the FLAG
epitope was also transfected as a control to determine the
background binding activities (Figure 2A, lanes 13–18).
These pull-down experiments showed that two N-terminal
deletion mutants of DGCR8 (DG276–773 and DG484–773),
in addition to the wild-type protein (WT), efﬁciently bind
Drosha-FLAG (Figure 2A). In contrast, the C-terminal dele-
tion mutants of DGCR8 (DG1–483, DG1–614 and DG1–692)
do not interact with Drosha-FLAG (Figure 2A). Therefore,
the C-terminal region of DGCR8 is important for the interac-
tion between DGCR8 and Drosha, whereas the N-terminal
region, containing the putative WW domain, is dispensable
for this binding. Previously, the WW domain of DGCR8/
Pasha has been predicted to interact with the proline-rich
region of Drosha (39). However, taken together with our
previous ﬁnding that the proline-rich region of human
Drosha is dispensable for DGCR8 binding (12), our current
ﬁndings demonstrate that the C-terminus of DGCR8, and
not the WW domain, is responsible for the association with
Drosha.
To elucidate the Drosha-binding domain of DGCR8 more
precisely, we generated two additional deletion mutants,
DG484–750 and DG484–738, which contain smaller
deletions at the C-terminus of this protein (Figure 1). These
truncation mutants were prepared in TnT reaction and used
for in vitro binding assays (Figure 2B). DG484–750 was
found to interact with Drosha, whilst DG484–738, which is
Figure 1. DGCR8 mutants used in this study. Asterisks represent the sites of
point mutagenesis.
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Drosha, indicating that the C-terminal residues 739–750 of
DGCR8 are critical for Drosha-binding (Figure 2B, lanes
7 and 8). It is noteworthy that this region is highly conserved
among the DGCR8/Pasha homologues of various species
(Supplementary Figure S1).
We performed additional pull-down experiments to test
the Drosha-binding ability of three point mutants of
DGCR8; mDRBD1, mDRBD2 and mDRBD1&2 (Figure 1).
Point mutagenesis was carried out to substitute the highly
conserved alanines (568 and 569) in dsRBD1 to lysine resi-
dues (mDRBD1). Similarly, the conserved alanine and serine
residues at positions 676 and 677 of dsRBD2 were also con-
verted to lysine residues (mDRBD2) (Figure 1). Each of these
mutant proteins were capable of binding Drosha, although the
dsRBD2 mutations (mDRBD2 and mDRBD1&2) slightly
affected the binding activity (Figure 2C, lanes 7 and 8).
These results were conﬁrmed by co-immunoprecipitated
(co-IP) experiment followed by western blot analysis
(Figure 2D). For this, the DGCR8 mutants were expressed
as FLAG-tagged proteins together with V5-tagged Drosha
protein in HEK293T cells. The mutants, DG484-773
and DG484-750 co-precipitated Drosha-V5 efﬁciently
whereas the mutant DG484–738 failed to precipitate
Drosha-V5, demonstrating that the C-terminal residues of
DGCR8 are important for the Drosha–DGCR8 interaction
(Figure 2D).
It is noted that when DGCR8 was overexpressed, Drosha
protein level was also increased (Figure 2D, compare lanes
1 and 2). Moreover, the DGCR8 mutants that retain the
Drosha-binding activity had the same effect on Drosha pro-
tein level (Figure 2D, lanes 3 and 4). This result suggests
that DGCR8 may stabilize Drosha through protein–protein
interaction.
Figure 2. Identification of the Drosha-interacting domain. (A–C) In vitro binding assay. DGCR8 wild-type and the indicated mutant proteins were synthesized by
TnT (in vitro transcription and translation, Invitrogen) reactions and incubated with the Drosha-FLAG protein immobilized on anti-FLAG antibody that is
conjugated on agarose beads. The left panels show 10% of the input proteins used in the binding reactions, whereas the middle panels visualize the proteins
interacting with Drosha-FLAG. As a control (right panels, pull-down with FLAG), an empty vector expressing FLAG tag only was transfected and the cell lysates
were used for immunoprecipitation. (D) Immunoprecipitation followed by western blot analysis. FLAG-DGCR8 mutant constructs were co-expressed with
Drosha-V5. Immunoprecipitation was performed with anti-FLAG antibody and western blotting was carried out using either anti-V5 antibody (upper panels) or
anti-FLAG antibody (lower panels).
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pri-miRNA binding
To determine the exact region of the DGCR8 protein that is
required for pri-miRNA binding, we utilized four deletion
mutants (DG276–773, DG484–773, DG1–483 and DG1–
614) and three point mutants (mDRBD1, mDRBD2 and
mDRBD1&2) in UV-crosslinking experiments (Figure 3A
and B). These proteins were transiently expressed and
immunopuriﬁed from HEK293T cells by extensive washing
with high salt buffer containing 2.5 M NaCl to remove
Drosha, as described previously (12). The immunopuriﬁed
mutant proteins were then UV-crosslinked to radiolabeled
pri-miR-16-1 transcripts. Both the N-terminal deletion
mutants (DG276–773 and DG484–773), which retain two
intact dsRBDs, bound the pri-miRNAs as efﬁciently as the
wild-type protein, whereas the mutants, DG1–483 and
DG1–614, lacking the dsRBDs, were deﬁcient in this binding
(Figure 3A). This result indicates that the C-terminal region
of DGCR8 containing the two dsRBDs is required for pri-
miRNA binding. The dsRBD point mutants (mDRBD1,
mDRBD2 and mDRBD1&2) had also lost RNA binding
activity, as indicated by both UV-crosslinking analysis
(Figure 3B) and gel retardation assays (Figure 3C), further
conﬁrming that both dsRBDs in DGCR8 are required for
pri-miRNA binding.
Figure 3. DGCR8 domains responsible for pri-miRNA binding. (A) UV-
crosslinking experiments between a series of DGCR8 deletion mutants
and
32P-UTP radiolabeled pri-miR-16-1. After UV-crosslinking, residual
RNA was removed by treatment with an RNase A/T1 mix. The left
panel visualizes the radioactivity associated with recombinant FLAG-
DGCR8 proteins, whereas the right panel indicates the amounts of protein
used in this experiment as visualized by silver staining. (B) UV-crosslinking
between a series of DGCR8 point mutants and
32P-UTP radiolabeled pri-
miR-16-1. The upper panel displays the radioactivity crosslinked to the
immunopurified FLAG-DGCR8 proteins and the lower panel indicates
the amount of protein used in this experiment as determined by silver
staining. (C) Gel retardation assay of pri-miR-30a binding to DGCR8
point mutants. Recombinant DGCR8 proteins prepared from E.coli were
pre-treated with thrombin to separate the GST tag prior to the assay.
The lower panel shows silver stained gel of recombinant DGCR8 protein
used in this experiment.
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Figure 4. DGCR8 domains required for pri-miRNA processing. In vitro pri-
miRNA processing assay of DGCR8 mutants. FLAG-DGCR8 was immuno-
precipitated using anti-FLAG antibody-conjugated agarose beads in low salt
buffer (buffer D-K0200), and subsequently subjected to an in vitro pri-miRNA
processing assay. Pri-miR-16-1 or pri-let-7a-1, labeled internally with
32P-
UTP, was used as the substrate. Decade markers (Ambion) were used as the
size markers.
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To investigate how the various mutations that we introduced
into the DGCR8 protein would affect the pri-miRNA proces-
sing activity of the Microprocessor complex, an in vitro pro-
cessing assay was carried out using DGCR8 proteins
immunoprecipitated with low salt buffer (buffer D-K0200
containing 200 mM KCl). This was done to ensure that the
endogenous Drosha protein would be co-IP (12). First, the
deletion mutants were incubated with either pri-let-7a-1 or
pri-miR-16-1 substrates to allow pri-miRNA processing by
the Microprocessor complex (Figure 4). As expected, four
DGCR8 mutants (DG1–483, DG1–614, DG1–692 and
DG484–738) that lack the Drosha-binding domain were deﬁ-
cient in pri-miRNA cleavage activity (Figure 4B, lanes 3–5
and C, lane 4). In contrast, both the N-terminal deletion
mutants and one C-terminal deletion mutant of DGCR8
(DG276–773, DG484–773 and DG484–750) efﬁcien-
tly cleaved pri-miRNA into pre-miRNA, indicating that the
N-terminal residues 1–483 and C-terminal residues 751–773
are dispensable for pri-miRNA processing in vitro
(Figure 4A, lanes 3 and 4 and C, lane 5). We next tested
our three dsRBD point mutants in these assays as they
bind poorly to pri-miRNA, and found that the alanine
point mutation in each of the dsRBDs (mDRBD1 or
mDRBD2) signiﬁcantly reduced the pri-miRNA processing
activity of DGCR8 (Figure 4D, lanes 3 and 4). In addition,
a combination of these substitutions (mDRBD1&2) almost
completely abolished the processing activity (Figure 4D,
lane 5). Hence, the RNA binding activity of DGCR8 may
be required to enable Microprocessor to recognize and pro-
cess pri-miRNAs.
Nuclear localization of DGCR8
To examine the subcellular localization of DGCR8, we per-
formed immunoﬂuorescence studies using ectopically
expressed, V5-tagged DGCR8 wild-type and mutant proteins
(Figure 5). Wild-type DGCR8 was found to be restricted in
the nucleus of HeLa cells (Figure 5, WT). We subsequently
analyzed the localization pattern of our DGCR8 deletion
mutants to determine the regions of the protein that were
important for this nuclear localization. The N-terminal trun-
cation mutant, DG276-773, was detectable throughout the
cell (Figure 5), indicating that the nuclear localization signal
and/or nuclear retention signal for DGCR8 is contained
within its N-terminal 275 residues. A similar localization pat-
tern was observed for another N-terminal deletion mutant,
DG484–773 (Figure 5). Consistently, three C-terminal dele-
tion mutants, DG1–483, DG1–614 and DG1–692 were
detected in the nucleus (Figure 5, DG1–692), further indicat-
ing that the nuclear localization/retention signal of DGCR8
may be conﬁned in its N-terminal region.
DISCUSSION
A summary of the results of our current DGCR8 mutagenesis
study is shown in Figure 6. A relatively small region of the
DGCR8 protein (residues 484 through 750) was found to be
sufﬁcient to facilitate pre-miRNA processing in vitro. This
minimal region of DGCR8 contains both the dsRBDs and
the C-terminal Drosha-binding domain. The N-terminal
region was not critical for processing but was shown to be
important for nuclear localization of DGCR8.
DGCR8 is capable of direct interaction with pri-miRNA.
On the contrary, we could not detect any signiﬁcant pri-
miRNA binding activity for Drosha in any of our assays
(including gel mobility shift assays, UV-crosslinking,
immunoprecipitations and GST pull-downs) (data not
shown). Thus, DGCR8 may be the primary factor that recog-
nizes the pri-miRNA structure, whereas Drosha interacts only
with the RNA substrates transiently during catalysis. In
addition, DGCR8 appears to stabilize the Drosha protein
through its C-terminal Drosha-binding domain. It will be of
great interest in the future to resolve the 3D structure of
pri-miRNA and the Drosha–DGCR8 complex to fully deci-
pher the associations between the substrate and the enzyme
complex.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
Figure 5. Subcellular localization of DGCR8 and its deletion mutants. HeLa
cells were transiently transfected with V5-tagged constructs, including WT
DGCR8, and the DG276–773, DG484–773, DG1–483, DG1–614 and DG1–
692 mutants. The left panels show DGCR8 protein signals visualized with
rabbit anti-V5 serum (1:500) and Alexa Flour 594 goat anti-rabbit IgG
(1:400). The middle panels show DAPI staining of the nucleus and the right
panels display an overlay of these two signals.
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